Which of the following electrolytes should be monitored while administering Triamterene drug?

RRB Nsg. Superintendent - 29 April 2025 (Shift-3rd)

Pharmacology

Medium

Appeared in: RRB Nsg. Superintendent - 29 April 2025 (Shift-3rd)

Explanation

Triamterene is classified as a potassium-sparing diuretic.
Its mechanism involves blocking sodium channels in the distal nephron, which increases sodium and water excretion while simultaneously reducing potassium excretion.
This potassium retention creates a significant risk for hyperkalemia (serum potassium > 5.0 mEq/L), the most dangerous adverse effect.
Hyperkalemia can lead to severe cardiac dysrhythmias, making potassium level monitoring essential for patient safety.

Option A: While chloride levels can be affected by diuretics as it often follows sodium, it is not the primary or most dangerous electrolyte to monitor with Triamterene. The risk of life-threatening hyperkalemia is the main concern.
Option C: Triamterene is designed to cause sodium excretion (natriuresis). While severe hyponatremia is possible, it is a part of the drug's intended therapeutic effect, and the risk is generally considered less acute and life-threatening than hyperkalemia.
Option D: Triamterene can cause a mild metabolic acidosis by reducing hydrogen ion secretion, which would affect bicarbonate levels. However, this is a less common and far less dangerous side effect compared to the immediate risk of cardiac events from hyperkalemia.

Visual 1: Diagram: Illustration of a nephron showing the sites of action for different classes of diuretics (Loop, Thiazide, Potassium-sparing), highlighting Triamterene's action on the distal tubule and collecting duct.
Visual 2: Chart: A summary table of diuretic classes, their examples, primary electrolyte concerns (hyperkalemia vs. hypokalemia), and key nursing considerations.
Visual 3: ECG Strip: Example of an ECG showing peaked T-waves, a characteristic sign of hyperkalemia, to emphasize the cardiac risk.

Clinical Relevance

Nursing practice connection: Knowing Pharmacological monitoring of potassium-sparing diuretics helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses must educate patients taking Triamterene to avoid high-potassium foods (like bananas, oranges, spinach, and potatoes) and salt substitutes containing potassium chloride.
It is a critical nursing responsibility to review the patient's medication list for other drugs that can increase potassium, such as ACE inhibitors (e.g., lisinopril), ARBs (e.g., losartan), or potassium supplements. This combination significantly increases the risk of severe hyperkalemia.
What if? If a patient on Triamterene reports new-onset muscle weakness, fatigue, and palpitations, the nurse should suspect hyperkalemia, hold the medication, notify the provider immediately, and prepare for an ECG and a stat potassium level check.

How to Approach the Question

First, identify the drug mentioned in the question: Triamterene.
Next, classify the drug. Recall or identify that Triamterene is a potassium-sparing diuretic.
The name 'potassium-sparing' is a major clue. It directly tells you the drug's effect on potassium—it saves or retains it in the body.
Consider the consequence of retaining too much of an electrolyte. For potassium, this leads to hyperkalemia (high potassium levels).
Evaluate the options based on this primary risk. Monitoring potassium is essential to prevent the life-threatening cardiac complications of hyperkalemia.
Therefore, the most critical electrolyte to monitor for a patient on a potassium-sparing diuretic is the potassium level.

Concept Tested & Keywords

QI_mAMQsc5vbYy0F2jExW7